Description

Retatrutide 16 mg is an advanced research peptide in development for weight management and metabolic health. As a triple receptor agonist (GLP‑1, GIP, and glucagon), it enhances insulin sensitivity, reduces appetite, and promotes significant body weight reduction.

This 16 mg dose is often used as an upper mid-to-high dose in clinical trials, typically following titration from 2 mg → 5 mg → 8 mg → 10 mg → 12 mg → 16 mg. Clinical studies indicate that this dose provides substantial weight-loss effects while maintaining a favorable safety profile.

⚠️ Status: Research-only, not yet approved for medical use (FDA/MHRA approval expected in upcoming years).

Key Features

• 💉 Dose: 16 mg weekly injection

• 🧬 Mechanism: Triple agonist – GLP‑1, GIP, and glucagon receptors

• ⚖️ Use: Advanced research dose for metabolic and obesity studies

• 🚫 Availability: Research-use only, not licensed for clinical treatment